NEWLINK GENETICS CORP's ticker is NLNK and the CUSIP is 651511107. A total of 112 filers reported holding NEWLINK GENETICS CORP in Q2 2017. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $8,971,000 | -33.9% | 881,274 | -52.3% | 0.09% | -39.4% |
| Q2 2017 | $13,568,000 | -74.3% | 1,846,000 | -15.8% | 0.14% | -76.3% |
| Q1 2017 | $52,820,000 | +158.0% | 2,191,700 | +10.0% | 0.60% | +129.5% |
| Q4 2016 | $20,475,000 | -29.7% | 1,991,700 | +2.8% | 0.26% | -21.4% |
| Q3 2016 | $29,113,000 | +63.5% | 1,938,300 | +22.6% | 0.33% | +78.5% |
| Q2 2016 | $17,808,000 | +19.8% | 1,581,506 | +93.6% | 0.19% | +19.2% |
| Q1 2016 | $14,870,000 | -57.2% | 817,006 | -14.5% | 0.16% | -50.5% |
| Q4 2015 | $34,764,000 | +36.2% | 955,306 | +34.1% | 0.32% | +22.1% |
| Q3 2015 | $25,529,000 | -5.4% | 712,306 | +44.4% | 0.26% | +12.2% |
| Q1 2015 | $26,988,000 | +578.9% | 493,300 | +393.3% | 0.23% | +505.3% |
| Q4 2014 | $3,975,000 | +85.6% | 100,000 | 0.0% | 0.04% | +72.7% |
| Q3 2014 | $2,142,000 | -19.3% | 100,000 | 0.0% | 0.02% | -29.0% |
| Q2 2014 | $2,655,000 | – | 100,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 93,533 | $962,000 | 1.69% |
| WALL STREET ASSOCIATES | 108,900 | $1,119,000 | 0.74% |
| NORTHWEST WEALTH MANAGEMENT, LLC | 57,482 | $591,000 | 0.60% |
| Orbimed Advisors | 1,991,700 | $20,475,000 | 0.26% |
| TFS CAPITAL LLC | 92,041 | $946,000 | 0.25% |
| Intrinsic Edge Capital Management LLC | 40,000 | $411,000 | 0.18% |
| SECOR Capital Advisors, LP | 100,529 | $1,033,000 | 0.13% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 176,077 | $1,810,000 | 0.12% |
| Piermont Capital Management Inc. | 41,400 | $426,000 | 0.10% |
| Vident Investment Advisory, LLC | 67,209 | $691,000 | 0.08% |